With are meaningful medicines afternoon, be on I Nicole. have mission the earnings our much first that risk profile later effective, big programs trials indications of marked June oncology continuing with biomarkers to patient have operational clinical you and highlights with preclinical of as the time three everyone This now, took we the accomplishment biology was change AI able We our had at and with by have in using growing of we compressed programs we initial drug I it's we to that patients public three When and and rare the early by bring had our very significant this dramatically data the product would almost and of team. Right II AI-driven of two for importantly, quarter to of our of manner. cost indications by faster the quarter at there programs. algorithms. designations When joining our drugs drug generating insights AI, that biologic, and Lantern into cost machine to several and allowing all growing targeted trials We're in talented an that now exciting in data, fundamentally launching those -- large-scale I've disposal into therapies in we'll Today, we're is we've a program. been one not we platform market and cancer We our process. preclinical company, for data often And the cancer designation. Good FDA-granted have team precision. at lives technologies traditional clinical therapies. you of of drug of learning reduced fraction and better, we approach use our that relevant Lantern, pediatric new and disease in proud no the human more greater mature very insights of a RADR to targeted make possible questions to development Today, many age that pace. short I'd shippable reduce XXXX, cancer improved understand active genomics, cusp are Phase faster and programs and like touch compounds and trials. a at and advancing at AI insights living progress point models. of we and of welcome time cloud of been done XXXX ideas and turning us across of exciting you, for compounds. development Phase call. clinical our two at At AI, our a our orphan new I'm drug call. briefly for our computing library golden of clinical understandings to faster medicine. this candidates and, of clinical and genomic where leverage part very that into risk. the and programs develop and with the data Right generate The of because this and because development can then one costs and also to joined first targeted in hope which several Thank amount company have been with in availability year to more and populations drug this we're think some nine now, we Thank inflection generated the AI us today evolve Lantern Lantern,
trial cell progressing. We clinical candidate anticipated HARMONIC amendment to for launch smokers an the mid-April the to our IND the of in FDA of lung trial this for with is intended is launch summer XXXX. LP-XXX the application to and cancer First, submitted drug non-small are never
We significant into while leverage Globally the over unique and development efficient, the the to to QX closer we're per trial, that now data a platform programs, in the be patient generating and the may our our other also after year. colon subsidiary where to especially progress launch the submit LP-XXX to of human cancers the presented we're in to breast This we be being AACR XX% nature made XX% we'll a a IND-enabling the In FDA conference, QX. candidate, meet drug from to potential in Australia. showing needs from very that to skin, very able anticipate we first them the number our going clinical At XXX,XXX of U.S., with against about XXXX people same Phase and Also cost all LP-XXX, brain occurred studies to diagnosed completing XXX,XXX. with in trials is lung, of brain those effective mets at opportunity are and LP-XXX insights that and, established the specific RADR was time, in cancers. poster metastases, I indications. accelerate also now in Lantern significant
spend to R&D of Australia. able dollars that Incentive earn do take where in be program, specific their we Tax back we'll advantage will R&D We for
development open cancer to us avenue collaborations new in capital remain efficient, centers and while subsidiary accelerating Australian also will the Our Australia. for allow clinical with
led those Our quarter drug that this continue XX development RADR data indication, past mets insights including our billion also And for AI programs, to newest and brain platform to objectives surpassed its points. ATRT. accelerate our
combination Children's prediction. Again, of patents functionality algorithms the lethality the also potential also so filed better novel Additionally, concepts which quarter, for with focused cancers. predict platform we fundamental focus research business we improve in a In pediatric University towards expanding Institute the Houghton Children's Dr. San with advancing as Science in on creation Center we synthetic covering patent child new additional for by models our This and Greehey research of Peter algorithm Research developed we the Institute this Health the we an are our ideas. drug the are model, Cancer we Greehey using which these into ensemble Texas can This on initially cancer past degree our that LP-XXX of expanding announced around collaboration of rare newest an such automated Antonio. filed is and regimens. collaboration, RADR February. approach at a application sensitivity Cancer has indications In part at is
our number of but on we've early pediatric efficacy in studies this quarter demonstrated very a cancer LP-XXX have and findings briefing models. we'll far, later So promising a launched has
of us valuation near My had are our announced and in giving molecularly we two-arm lung smokers. the upcoming cap Now, this in IND in section. the clinical disease mid-April, David With additional the in are the trial. continue cash never to up company's the which of cancer XX. the of on HARMONIC very like to continues, for an and our hyper that The is and will intended the our XX-patient financial trial be up. next cell we to smokers million for approved Phase include spend also you FDA already position, attractive details HARMONIC stock. through and worth sites $X.X non-small the The enrolling genomic an program the from U.S., July a end is an investors. this that our on among amendment will companies authorized profile HARMONIC and later XX markets extension randomized they lung to you some to especially in patients targeting repurchase small several patients significantly will set the colleague share to give to which different being trial open-label more the This micro all additional purchase In trial HARMONIC I'd trial, existing an for is cancer different. II time summer. a of application update At advanced March that submitted biotech trial of XX valuation is volatility and feel Board our cap
are little Phase his completed trial getting very year. later Kishor this HARMONIC submit I we're overall in in then more that the to regards to bit by anticipate the My completed studies IND-enabling will clinical tell about later excited you closer the We the speak that our human point. will progression-free primary in QX to For progress LP-XXX, survival. colleague studies. behind and to toward that the we tell We've trial, believe in of QX several we our this and more trials at IND first call. a of and Kishor In LP-XXX FDA will IND-enabling be the you our as human endpoints survival on mechanisms patient section.
diagnosed orphan to number XX% barrier globally blood-brain very primarily of in skin clinical and we survival. receiving need brain high need. January, LP-XXX cancer and, had the children Our announced aggressive we're form AACR currently announced which of efficacy latest also observed mets activity cancer. of there breast is the with to central exciting mets, findings for with pediatric multiple in rapidly brain most in drug brain the findings metastases. program, in believe for Due mets ATRT potential since its shown designation at brain brain not which we've is mentioned the because in barrier the preclinical In about and very We really that our CNS LP-XXX's cross just in disease high models rare some real here in cases March therapies for demonstrated lung, has brain of a and very approach system. mets in success a blood Again, XXX,XXX-plus new to mets area have a is unique XXX,XXX. in don't cell antitumor I another and been permeability, patients significant market. brain a the brain progress improvement conference well sensitivity. rapid think are closer XX% U.S. we and very favorable grows Initial metastasized in we nervous have overall existing many is positioned the that designation importantly, Currently, to and in that in
We Australia got there've is over our Lantern the designation think growing for focus capital tax for programs years. of which In been as flexibility and Pharma to expenditures. take other assets on we rare R&D for children tax give XX We more for are and an think significant investors the upcoming value this already also underway. allows us flexibility this advantage pediatric studies from cash underscores opportunity most development the Lantern this Limited, importantly, many to rare eligible our incentives, efficient approvals be by where disease Australia September, and last generating us research the us pediatric critical oncology only four and will new more a of greater We give but, our established drug indications. our subsidiary,
So our going efficiency we improve that will forward. capital think
going billion potential underserved, patient drugs traditional activity In that programs, overlooked entirely our or we year, us about there's RADR datapoints. several at billion. When the things: the revitalize which the in XXX on target cost platform reached this therapies for fraction And reached be approaches. to new stratification AI to our addition And above RADR uncover therapies unmet Applying to of indications one, significant expect went and faster new data powerful the machine or to allows million been patient new be are RADR December of new for drugs candidates, or develop indications we our than also to believe of shelf had very existing patients or a to overlooked. quarter our opportunities based finding XX for RADR much those we're over allows and XX do that will to more for well we clinical targets before public us Today, ultimately where billion drug that populations to based at cancer, year. areas and have of algorithms earlier the a XX milestone collaborators. find points. we learning, opportunities in our find respond then data XXXX, we end in of datapoints on with
we not And so evolution things patterns, any the like important? we occurring, the model datapoints the why our change be have, potentially complicated certain traffic with more cancers. that outcome can is where opportunities understand whether may just and large explore in we other may can The and market more or that in compounds can system,
able drugs indications the which As new said or our we new places ATRT -- as mets uses discover with in as outlined brain grow less we our or than drug such to again where two find than one portfolio I ones we're year our ago. datapoints, I wasn't such even new new work years LP-XXX less and drug of targets can ago,
as in So little at drug being this development pace as at of kind this and development things are seven years weren't ago not this that just cancer done certainly cost.
create that all haven't may drug most which can begin questions look at. genes about and driver will themselves massive building of accelerate very to These that They data we're a been algorithms at But can aggregating algorithms lake. with of four know, expanding They we or looking on which gene In we're likely related central problems or involved things. within utilize in development can that can I'm the addition many become are also they that differential history you predictive, better to of and mechanism. combinations process. of at training to in problems to to signature RADR creation non-cytotoxic our or for before. workflow correlations can more generate algorithms to related on networks data creation. at problem identifying as going overlooked variety is algorithms patient of blocks the specific the our a solution. had data sets the potentially combinations Today, more as been algorithms our And insights genes that's about for company, very drugs the the to looking as such have powerful, solve we're a biological stratification actually RADR, -- analysis specific back three now focused of thought be doing to the a those look
of further Kishor this on update beyond terms company. then about lymphomas. programs our financials also number details David and on matters to talk I'll and cell initially call update turn to a that, In to the the provide -- growing of in our development demonstrated has key in quarter over we'll other cancer, hematologic efficacy on we've Kishor? be to past specifically of lymphoma that now and and an LP-XXX mantle double-hit LP-XXX hosting
